Just a moment, the page is loading...

Externally Sponsored Research & Access Portal

At Regeneron, we move science to medicine because our world is meant for more.

Managed Access Program

1 / 4
2 / 4
3 / 4
4 / 4

Download PDF

Please find a link to our MAP Policy here: Managed Access Program Policy.

FAQs

  • Click on CREATE ACCOUNT in the top menu.
  • Refer to the instructions in the submission process guide above.
  • Use the "Forgot Password?" link to reset your password. Please enter the email address you are registered with, the code shown, and check for the password reset email. Please check your email for further instructions. Copy and paste the validation code from your email, click the “Validate” button, enter a new password, and complete the password reset.
  • If you do not receive the message, please check your spam folder. Otherwise, please start this process again.
  • You may view the status of your submission via the MY REQUESTS tab after you've logged into your account.
  • Managed Access Programs Requests

    Requests for individual patient treatment must be initiated by a treating physician; therefore, if you are a patient or caregiver, please ask your doctor for support in this process.

    Physicians should complete the individual patient treatment requests and follow the application prompts. Regeneron will acknowledge receipt of a physician’s request within five business days.

    When reviewing an individual patient MAP request, Regeneron considers key criteria, including but not limited to the following factors:

    1. There are sufficient data to expect that the investigational product will have a favorable benefit-risk profile.
    2. The regulatory agency in the country where the patient resides must also approve the proposed use of the investigational product, when required.
    3. Providing the investigational product will not interfere with or compromise its clinical development. This means that adequate supply of the investigational product must be available to perform necessary clinical studies before access is provided through the MAP and that the patient is ineligible to participate in a study in the development program.
    4. There is a legitimate medical need documented and submitted by the treating physician.
    5. The physician initiating the individual patient MAP request and providing treatment must be qualified in terms of background, education, and experience to carry out the proposed treatment.
    6. The initiating physician agrees to assume all responsibilities and obligations to comply with the relevant regulatory requirement.

    User Guidance

    User Guide and Forms Contacts and Other Assistance
    Guides
    • Portal User Guide
    Forms
    Questions for ESR: Questions for MAPs:
    Submit a Request
    Click here for the Regeneron Privacy Notice

    Regeneron is committed to conducting business in compliance with all Regeneron policies, American Medical Association (“AMA”) Guidelines on Gifts to Physicians, the AMA Ethical Opinion on Continuing Medical Education, the Pharmaceutical Research and Manufacturers of America (“PhRMA”) Code on Interactions with Healthcare Professionals, the Accreditation Council for Continuing Medical Education (“ACCME”) Standards for Commercial Support, the U.S. Food and Drug Administration (“FDA”) regulations and guidance, the U.S. Department of Health and Human Services Office of Inspector General (“OIG”) guidance, and all applicable federal and state laws and regulations.

    Copyright © 2026 Regeneron Pharmaceuticals Inc. All rights reserved. All trademarks mentioned are the property of their respective owners.